Phio Pharmaceuticals Corp. Secures $6.36 Million Through At The Market Offering
PUBLIC · PHIOApr 08, 2026
Amount Raised
$6.36 Million
Round Type
Post-IPO Equity
King Of PrussiaBiotechnologyHealthcareHealth CareTherapeutics
Investors
H.C. Wainwright & Co., LLC
Description
On April 8, 2026, Phio Pharmaceuticals Corp. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. The Company is set to offer and sell up to $6,360,000 of its common stock
Company Information
Company
Phio Pharmaceuticals
Location
411 SWEDELAND ROAD
King Of Prussia, Pennsylvania, United States
About
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.
Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future.
Fundz sees it the moment Phio Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
King Of PrussiaBiotechnologyHealthcareHealth CareTherapeutics